Pioneering cellular medicines for women’s health

We’re developing off-the-shelf cell therapies for high-impact women’s diseases, with lead programs in ovarian cancer, triple negative breast cancer and endometriosis.

Pioneering excellence in the field of immunotherapy

Cartherics creates precisely-defined immunotherapy treatments to combat a variety of cancers, endometriosis and Alzheimer’s disease. We combine the best components of immune targeting utilising gene editing and CAR technology to advance cell therapy to provide more diverse off-the-shelf treatments for patients. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer and beyond.

Learn more about us

Some of our partners

Latest news

Cartherics Makes February 2021 A Special Month

By Christine Filippis / February 24, 2021
It all happened at Cape Schanck ...... By Leigh Dayton 24 February 2021 2020 was a rough year everywhere for...
Read More

CAR-T Funding is Reaching Staggering New Heights

By Christine Filippis / February 23, 2021
A survey reveals nearly US$100 market capitalisation 23 February 2021 A survey conducted by Washington DC based BioInformant assesses the...
Read More

Cartherics CEO Alan Trounson on “3-person IVF”

By Christine Filippis / February 4, 2021
Legislation to be introduced to Australian Parliament By Leigh Dayton 4 February 2021 Not only is Alan Trounson Cartherics CEO...
Read More